Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects of gefitinib in treating patients with
metastatic or unresectable head and neck cancer or non-small cell lung cancer. Gefitinib may
stop the growth of cancer cells by blocking the enzymes necessary for their growth